Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy

Genomics. 2015 Dec;106(6):348-54. doi: 10.1016/j.ygeno.2015.10.002. Epub 2015 Oct 21.


DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.

Keywords: 5-FU; Chemotherapy; Colorectal cancer; DNA methylation; HYAL2; Predictive marker; Prognostic marker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use
  • Cell Adhesion Molecules / genetics*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / genetics*
  • Colonic Neoplasms / pathology
  • CpG Islands / genetics
  • DNA Methylation*
  • Disease-Free Survival
  • Female
  • Fluorouracil / therapeutic use*
  • Follow-Up Studies
  • GPI-Linked Proteins / genetics
  • Humans
  • Hyaluronoglucosaminidase / genetics*
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Prognosis
  • Regression Analysis
  • Treatment Outcome


  • Antimetabolites, Antineoplastic
  • Cell Adhesion Molecules
  • GPI-Linked Proteins
  • Hyal2 protein, human
  • Hyaluronoglucosaminidase
  • Fluorouracil